Friday 16 October 2026
Export ADCT’s income statement to Excel — free account
ADC Therapeutics SA
ADCT Healthcare Biotechnology
ADC Therapeutics SA’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.17%, EPS grew 78.0%, free cash flow grew 51.0% and total debt rose 1.87%, each against the same quarter a year earlier.
1.41
0.08
−5.37%
Follow ADCT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
7.26 | 5.51 | 7.30 | 2.08 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(18.42) | (14.41) | (19.46) | (14.05) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.86 | 3.72 | 5.84 | 0.80 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.34) | (2.14) | (4.04) | (0.62) | |
EV/FCF |
(3.33) | (2.15) | (4.06) | (0.62) | |
Quick Ratio |
4.15 | 4.14 | 3.87 | 2.86 | |
Current Ratio |
4.63 | 4.37 | 4.09 | 3.03 | |
Net Debt/EBITDA |
3.86 | 8.19 | 4.59 | 4.03 | |
Debt/Assets |
39.76% | 35.73% | 39.68% | 41.74% | |
Debt/Equity |
(0.48) | (0.62) | (0.53) | (0.51) | |
Asset Turnover |
0.24 | 0.25 | 0.28 | 0.26 | |
Operating CF/Net income |
0.72 | 4.86 | 0.90 | 0.71 | |
Capex/Depreciation |
0.00 | 5.83 | (0.28) | 0.00 | |
Interest Coverage |
(2.31) | (1.38) | (2.04) | (1.88) | |
Research and Development Expense of Revenue |
163.16% | 78.86% | 95.33% | 90.22% | |
Selling, General and Administrative Expense of Revenue |
115.75% | 92.99% | 108.41% | 115.72% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
12.18% | 2.92% | 11.71% | 23.64% | |
Graham Net Nets |
(0.44) | (0.45) | (0.40) | (1.48) | |
Graham Number |
7.55 | 6.28 | 5.76 | 4.68 | |
Earnings Yield |
(36.25%) | (33.99%) | (28.00%) | (61.68%) | |
Free Cash Flow Yield |
(24.25%) | (31.40%) | (19.72%) | (61.32%) | |
Revenue per Share |
0.12 | 0.18 | 0.14 | 0.12 | |
Operating CF per Share |
(0.22) | (0.24) | (0.19) | (0.08) | |
Capex per Share |
0.00 | 0.01 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.22) | (0.24) | (0.19) | (0.08) | |
Cash per Share |
1.72 | 2.06 | 1.50 | 1.41 | |
Shareholders Equity per Share |
(1.75) | (1.46) | (1.40) | (1.47) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.75) | (1.46) | (1.40) | (1.47) | |
Free Cash Flow |
(29.63) | (30.46) | (29.74) | (11.81) | |
Working Capital |
225.11 | 236.17 | 209.14 | 175.38 | |
Capital Expenditures |
0.00 | 0.66 | (0.03) | 0.00 | |
Net Current Asset Value |
(240.79) | (202.65) | (231.10) | (245.88) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | (0.03) | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
23.47 | 24.72 | 31.40 | 27.11 | |
Average Payables |
11.25 | 13.60 | 10.44 | 11.19 | |
Average Inventory |
17.06 | 3.22 | 11.11 | 11.35 | |
Average Assets |
319.42 | 322.57 | 282.02 | 300.47 | |
Average Common Equity |
(205.06) | (194.24) | (227.30) | (213.69) |
Columns are period end dates